{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:58:08Z","timestamp":1761101888511},"reference-count":66,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Clinical Epidemiology"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1016\/j.jclinepi.2009.09.006","type":"journal-article","created":{"date-parts":[[2009,12,8]],"date-time":"2009-12-08T15:07:52Z","timestamp":1260284872000},"page":"960-969","source":"Crossref","is-referenced-by-count":33,"title":["Expectations, validity, and reality in pharmacogenetics"],"prefix":"10.1016","volume":"63","author":[{"given":"Nita A.","family":"Limdi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David L.","family":"Veenstra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jclinepi.2009.09.006_bib1","doi-asserted-by":"crossref","first-page":"755","DOI":"10.7326\/0003-4819-147-11-200712040-00006","article-title":"Medication use leading to emergency department visits for adverse drug events in older adults","volume":"147","author":"Budnitz","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib2","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1001\/jama.279.15.1200","article-title":"Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies","volume":"279","author":"Lazarou","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib3","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1001\/archinte.167.16.1752","article-title":"Serious adverse drug events reported to the Food and Drug Administration, 1998\u20132005","volume":"167","author":"Moore","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib4","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1056\/NEJMe0708842","article-title":"Pharmacogenomic biomarkers for prediction of severe adverse drug reactions","volume":"358","author":"Ingelman-Sundberg","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib5","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1681\/ASN.2005121346","article-title":"Pharmacogenomics and pharmacogenetics of hypertension: update and perspectives\u2013the adducin paradigm","volume":"17","author":"Manunta","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib6","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/sj.tpj.6500395","article-title":"Antihypertensive therapy, the alpha-adducin polymorphism, and cardiovascular disease in high-risk hypertensive persons: the Genetics of Hypertension-Associated Treatment Study","volume":"7","author":"Davis","year":"2007","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib7","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.ahj.2008.03.007","article-title":"Alpha-adducin polymorphism associated with increased risk of adverse cardiovascular outcomes: results from GENEtic Substudy of the INternational VErapamil SR-trandolapril STudy (INVEST-GENES)","volume":"156","author":"Gerhard","year":"2008","journal-title":"Am Heart J"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib8","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/sj.ejhg.5201632","article-title":"The influence of the alpha-adducin G460W polymorphism and angiotensinogen M235T polymorphism on antihypertensive medication and blood pressure","volume":"14","author":"Schelleman","year":"2006","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib9","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1161\/01.CIR.0000153341.46271.40","article-title":"Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects","volume":"111","author":"Boekholdt","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib10","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1097\/01.hjh.0000173510.52987.68","article-title":"Pharmacogenomics of blood pressure response to antihypertensive treatment","volume":"23","author":"Mellen","year":"2005","journal-title":"J Hypertens"},{"issue":"3","key":"10.1016\/j.jclinepi.2009.09.006_bib11","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1371\/journal.pone.0000289","article-title":"ADRB2 Arg16Gly polymorphism, lung function, and mortality: results from the Atherosclerosis Risk in Communities study","volume":"2","author":"Ferdinands","year":"2007","journal-title":"PLoS One"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib12","first-page":"209","article-title":"The pharmacogenetics of asthma: an update","volume":"7","author":"Tantisira","year":"2005","journal-title":"Curr Opin Mol Ther"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib13","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/ncpcardio0309","article-title":"Mechanisms of disease: beta-adrenergic receptors\u2013alterations in signal transduction and pharmacogenomics in heart failure","volume":"2","author":"Feldman","year":"2005","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib14","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1080\/07853890600551045","article-title":"Pharmacogenomics and antidepressant drugs","volume":"38","author":"Binder","year":"2006","journal-title":"Ann Med"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib15","first-page":"1","article-title":"Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs)","volume":"146","author":"Matchar","year":"2007","journal-title":"Evid Rep Technol Assess (Full Rep)"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib16","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1093\/aje\/kwi201","article-title":"A network of investigator networks in human genome epidemiology","volume":"162","author":"Ioannidis","year":"2005","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/ng0106-3","article-title":"A road map for efficient and reliable human genome epidemiology","volume":"38","author":"Ioannidis","year":"2006","journal-title":"Nat Genet"},{"issue":"6","key":"10.1016\/j.jclinepi.2009.09.006_bib18","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.1371\/journal.pmed.0040211","article-title":"Reporting of systematic reviews: the challenge of genetic association studies","volume":"4","author":"Khoury","year":"2007","journal-title":"PLoS Med"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib19","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa0809329","article-title":"Estimation of the warfarin dose with clinical and pharmacogenetic data","volume":"360","author":"Klein","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib20","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1001\/archinte.168.21.2304","article-title":"Assessing new biomarkers and predictive models for use in clinical practice: a clinician's guide","volume":"168","author":"McGeechan","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib21","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1592\/phco.28.9.1084","article-title":"Warfarin pharmacogenetics","volume":"28","author":"Limdi","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib22","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2008-01-134247","article-title":"A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose","volume":"112","author":"Cooper","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib23","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.2217\/14622416.9.10.1445","article-title":"VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans","volume":"9","author":"Limdi","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib24","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1161\/CIRCULATIONAHA.107.737312","article-title":"Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation","volume":"116","author":"Anderson","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.clpt.2006.04.006","article-title":"VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation","volume":"80","author":"Schalekamp","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib26","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/sj.clpt.6100036","article-title":"VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement","volume":"81","author":"Schalekamp","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib27","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.clpt.2004.08.006","article-title":"Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status","volume":"76","author":"Schalekamp","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib28","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.clpt.2003.12.017","article-title":"Acenocoumarol stabilization is delayed in CYP2C93 carriers","volume":"75","author":"Schalekamp","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib29","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/sj.clpt.6100144","article-title":"Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians","volume":"81","author":"Schelleman","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib30","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1182\/blood.V96.5.1816","article-title":"Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment","volume":"96","author":"Taube","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib31","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1056\/NEJMoa0708078","article-title":"Genetic determinants of response to warfarin during initial anticoagulation","volume":"358","author":"Schwarz","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib32","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(98)04474-2","article-title":"Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications","volume":"353","author":"Aithal","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib33","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1055\/s-0037-1614114","article-title":"Genetic modulation of oral anticoagulation with warfarin","volume":"84","author":"Margaglione","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib34","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1001\/jama.287.13.1690","article-title":"Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy","volume":"287","author":"Higashi","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib35","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/sj.clpt.6100290","article-title":"Influence of CYP2C9 and VKORC1 1173C\/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin","volume":"83","author":"Limdi","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib36","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1160\/TH07-09-0552","article-title":"An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients","volume":"100","author":"Meckley","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib37","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-150-2-200901200-00005","article-title":"Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation","volume":"150","author":"Eckman","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib38","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/clpt.2008.133","article-title":"The critical path of warfarin dosing: finding an optimal dosing strategy using pharmacogenetics","volume":"84","author":"Lesko","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib39","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2217\/17410541.5.3.279","article-title":"Healthcare impact of personalized medicine using genetic testing: an exploratory analysis for warfarin","volume":"5","author":"McWilliam","year":"2008","journal-title":"Per Med"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib40","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199411103311906","article-title":"Severe adverse cutaneous reactions to drugs","volume":"331","author":"Roujeau","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib41","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/j.1468-3083.2006.02082.x","article-title":"Toxic epidermal necrolysis: 15 years' experience in a Dutch burns centre","volume":"21","author":"Gerdts","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib42","first-page":"119","article-title":"Toxic epidermal necrolysis and Steven Johnson syndrome: 11-years experience and outcome","volume":"11","author":"Gravante","year":"2007","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib43","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/428486a","article-title":"Medical genetics: a marker for Stevens-Johnson syndrome","volume":"428","author":"Chung","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib44","doi-asserted-by":"crossref","first-page":"28S","DOI":"10.1111\/1523-1747.ep12388434","article-title":"The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification","volume":"102","author":"Roujeau","year":"1994","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib45","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/01.fpc.0000199500.46842.4a","article-title":"Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions","volume":"16","author":"Hung","year":"2006","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib46","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/sj.tpj.6500356","article-title":"A marker for Stevens-Johnson syndrome: ethnicity matters","volume":"6","author":"Lonjou","year":"2006","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib47","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2217\/14622416.7.6.813","article-title":"HLA-B locus in Caucasian patients with carbamazepine hypersensitivity","volume":"7","author":"Alfirevic","year":"2006","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib48","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.2217\/14622416.9.10.1543","article-title":"Carbamazepine, HLA-B\u22171502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations","volume":"9","author":"Ferrell","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1528-1167.2008.01716.x","article-title":"The clinical impact of pharmacogenetics on the treatment of epilepsy","volume":"50","author":"Loscher","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib50","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib51","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.clpt.2006.03.013","article-title":"Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment","volume":"80","author":"Borges","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib52","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s10549-006-9428-0","article-title":"The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen","volume":"101","author":"Goetz","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib53","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1200\/JCO.2007.12.2705","article-title":"Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes","volume":"25","author":"Schroth","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib54","doi-asserted-by":"crossref","first-page":"9312","DOI":"10.1200\/JCO.2005.03.3266","article-title":"Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes","volume":"23","author":"Goetz","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib55","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(04)17666-6","article-title":"Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer","volume":"365","author":"Howell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib56","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1093\/jnci\/djn100","article-title":"Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis","volume":"100","author":"Punglia","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib57","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s10549-004-7751-x","article-title":"Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients","volume":"91","author":"Nowell","year":"2005","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.jclinepi.2009.09.006_bib58","doi-asserted-by":"crossref","first-page":"R7","DOI":"10.1186\/bcr1640","article-title":"Genetic vatiants of CYP3A5, CYP2D6, SULT1A1, UGT2B15, and tamoxifen response in postmenopausal patients with breast cancer","volume":"9","author":"Wegmen","year":"2007","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib59","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/tpj.2009.14","article-title":"Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients","volume":"4","author":"Rae","year":"2009","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib60","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1093\/jnci\/djn127","article-title":"A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients?","volume":"100","author":"Hayes","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib61","doi-asserted-by":"crossref","first-page":"R156","DOI":"10.1093\/hmg\/ddn289","article-title":"Genome-wide association studies: potential next steps on a genetic journey","volume":"17","author":"McCarthy","year":"2008","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib62","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/nrg1229","article-title":"Pharmacogenetics goes genomic","volume":"4","author":"Goldstein","year":"2003","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib63","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2008-04-147884","article-title":"Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis","volume":"112","author":"Sarasquete","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib64","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/FPC.0b013e3282f70492","article-title":"Pathway-based association analysis of genome-wide screening data suggest that genes associated with the gamma-aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia","volume":"18","author":"Inada","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib65","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/clpt.2008.131","article-title":"Warfarin and pharmacogenomic testing: the case for restraint","volume":"84","author":"Garcia","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jclinepi.2009.09.006_bib66","doi-asserted-by":"crossref","first-page":"511","DOI":"10.7326\/0003-4819-118-7-199304010-00005","article-title":"Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group","volume":"118","author":"Fihn","year":"1993","journal-title":"Ann Intern Med"}],"container-title":["Journal of Clinical Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089543560900300X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089543560900300X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,24]],"date-time":"2020-05-24T04:01:50Z","timestamp":1590292910000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S089543560900300X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":66,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S089543560900300X"],"URL":"https:\/\/doi.org\/10.1016\/j.jclinepi.2009.09.006","relation":{},"ISSN":["0895-4356"],"issn-type":[{"value":"0895-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}